Clinical trial
Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit…
NCT00116363 · Introgen Therapeutics, Industry · Unknown status
Key facts
| NCT number | NCT00116363 |
|---|---|
| Title | Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma |
| Official title | Phase II Study Examining the Biological Efficacy of Intratumoral INGN 241 (Ad-mda7) Administration in Patients With In Transit Melanoma |
| Lead sponsor | Introgen Therapeutics, Industry |
| Collaborators | M.D. Anderson Cancer Center |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Melanoma, Neoplasm Metastasis |
| Intervention type | Genetic |
| Interventions | investigational drug INGN 241 |
| Enrollment | 25 |
| Start date | Mar 1, 2005 |
| Completion | Dec 1, 2006 |
| First posted | Jun 29, 2005 |
| Last update posted | Apr 1, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: